Stay updated on Talimogene Laherparepvec and Nivolumab Combination Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec and Nivolumab Combination Clinical Trial page.

Latest updates to the Talimogene Laherparepvec and Nivolumab Combination Clinical Trial page
- Check5 days agoChange DetectedThe page's revision label was updated from v3.5.2 to v3.5.3, indicating a minor update to the page version.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded revision entries for v3.5.2 on 2026-04-09 and 2026-04-13. Removed revision entry for v3.5.0 on 2026-04-07 and 2026-04-08.SummaryDifference0.2%

- Check26 days agoChange DetectedTwo new entries were added to the study record on 2026-04-07 and 2026-04-08, and two entries were removed on 2026-03-31 and 2026-04-01.SummaryDifference0.1%

- Check34 days agoChange DetectedAdded Eccrine porocarcinoma and Cutaneous neuroendocrine carcinoma to the inclusion criteria; two other tumor types were removed on 2026-03-24 and 2026-03-25.SummaryDifference0.2%

- Check41 days agoChange DetectedUpdates to the study record were made on 2026-03-24 and 2026-03-25, with deletions on 2026-03-17 and 2026-03-18.SummaryDifference0.2%

- Check48 days agoChange DetectedRevision updates to version v3.5.0 were applied on 2026-03-17 and 2026-03-18, replacing the previous v3.4.3 from 2026-03-10 and 2026-03-11.SummaryDifference0.1%

Stay in the know with updates to Talimogene Laherparepvec and Nivolumab Combination Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec and Nivolumab Combination Clinical Trial page.